Flyte Aviation Posts Record Q3 Revenue of $1.84M, Up 145% Sequentially, But Cash Falls to $2.4M
VJET is trading near its 52-week low of $0.437 (7.7% above the low) on light trading volume (0.2× avg).
Summary
Flyte Aviation reported record Q3 2026 aviation revenue of $1.84M, up 145% sequentially, with flight hours up 129%, while cash stood at just $2.4M against a $1.9M quarterly loss from continuing operations.
Key Events · Earnings and Guidance · VJET
-
Record Q3 Aviation Revenue
Aviation revenue reached $1,838,000 for the quarter ended September 30, 2026, a 145% sequential increase, with flight hours up 129% after two aircraft were added to the fleet.
-
Thin Cash, Continuing Losses
The company reported a $1.9 million loss from continuing operations and held $2.4 million of cash as of September 30, 2026; the $15.1 million net loss includes a $13.3 million non-cash impairment on MedTech assets held for sale.
-
Fleet Additions in Q4
Three aircraft have completed lessor pre-purchase inspections and are expected to join the fleet and begin revenue flights in the December quarter, with more aircraft anticipated in the first half of 2027.
-
MedTech Sale Still Non-Binding
A November 1, 2026 non-binding LOI covers the VIVO, LockeT and associated cardiology assets, targeting a year-end 2026 close, but remains subject to due diligence, a definitive agreement and approvals.
Analysis · VJET · Industrial Applications And Services
Revenue is ramping fast off a tiny base — $1.84M for the quarter, up 145% sequentially — and the fleet now flies over 99% of customer trips on its own jets instead of paying for third-party charters, which is the core margin story. Against that, the company burned through the quarter with a $1.9M loss from continuing operations and ended September with just $2.4M of cash, so the aviation ramp is being funded from a very thin balance sheet. The $15.1M net loss is mostly a $13.3M non-cash write-down on the MedTech assets now classified as held for sale, not cash leaving the business. What would clean up the story and bring in capital is the pending non-binding LOI to sell those cardiology assets by year-end 2026; it is not signed and may not close.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VJET was trading at $0.47 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $931.2K. The 52-week trading range was $0.44 to $30.60. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.